Home Senseonics Holdings

Senseonics Holdings

Senseonics Exploring Strategic Options to Enhance Stakeholder Value

Board of Directors has decided to explore potential strategic alternatives to enhance stakeholder value. The Company is engaging Moelis & Company, LLC as its financial advisor and Cooley, LLP as its legal advisor.

FDA Approves to Continue the PROMISE Sensor Clinical Study in an Extended Cohort to 365 Days to Gather Feasibility Data

PROMISE Sensor Clinical Study is to evaluate the safety and efficacy of the Eversense CGM System in people with diabetes over a 180-day period for the pre-market application submission to the U.S.

Eversense® Bridge Patient Access Program Launched in the U.S.

3/22/19: Under the program, patients can access the Eversense CGM System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider. 

Senseonics to Present at the B. Riley & Co. Institutional Investor Conference

Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®,...

Senseonics and TypeZero Sign Development Agreement for Artificial Pancreas and Decision Support Systems

“We’re thrilled to partner with TypeZero with the goal of progressing the diabetes management field in providing...